As the chart shows, the stock price benefited from three large jumps in June, August, and December. Here's how it went down. In June, at the annual American Society of Clinical Oncology (ASCO) meeting ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T ...

Shares of Bluebird Bio BLUE were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in ...

Major developments in bluebird bio's neighborhood improved the biotech stock's outlook. A few days later, the FDA delivered a landmark approval for Kymriah, a cell-based treatment for younger patients ...

Clinical-stage gene therapy specialist bluebird bio (NASDAQ: BLUE) reported second-quarter earnings last week, which mostly just served as a reminder of its pipeline progress because revenue and ...

Every year, the Mystery Writers of America celebrates the best in mystery fiction, non-fiction, and television published or produced at the annual Edgar Awards. At this year's 72nd Gala Banquet, held ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

bluebird bio (NASDAQ: BLUE) reported fourth-quarter earnings after the closing bell on Wednesday. Without any products on the market, the quarterly pipeline update is more important than the revenue ...

Bluebird Bio Inc. (NASDAQ: BLUE) saw its shares dip on Wednesday after the firm announced the pricing of a secondary offering. The offering is expected to close by December 15 and is subject to ...

DURHAM – Potential therapies for several rare diseases and cancers will be manufactured in Durham, according to Cambridge, Mass.-based bluebird bio, which has purchased a 125,000-square foot ...